Last updated: February 17, 2026
What Is the Current Market Outlook for NDC 00378-6859?
NDC 00378-6859 refers to Tadalafil, marketed under the brand name Cialis. It primarily treats erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). The global market for tadalafil has seen consistent growth, driven by expanding indications, increasing prevalence of ED, and off-label use cases.
Market Size and Growth Trends
Global Market Size
As of 2022, the global ED drug market was valued at approximately $5.3 billion. Tadalafil accounted for roughly 45-50% of the market share, with revenue estimates around $2.4 billion.
CAGR Estimates
From 2022 to 2028, the market is projected to grow at a compound annual growth rate (CAGR) of approximately 6%. This growth stems from:
- Aging populations
- Rising awareness around sexual health
- Expanded indications including daily dosing options
Regional Demand
North America leads with about 45% of the global market, followed by Europe with 25%. Asia-Pacific exhibits the fastest growth due to increasing healthcare access and cultural shifts toward sexual health.
Competitive Landscape
Major manufacturers include Eli Lilly, Pfizer, and Teva. Lilly’s Cialis has maintained a dominant position, with newer entrants including generic versions following patent expiration. The expiration of patent rights in 2018 allowed multiple generics to enter the market, increasing price competition and lowering consumer prices.
Price Dynamics and Trends
Brand-Name Pricing
In the U.S., Cialis's retail price per 30-tablet pack (20 mg) ranges from $450 to $550, depending on pharmacies and insurance coverage.
Generic Pricing
Post-patent expiration, generics sell for approximately 50-70% less. Typical wholesale acquisition costs for generics have fallen to $100-$200 per 30-tablet pack of 20 mg.
Price Projections
Over the next five years:
- Brand-name Cialis is expected to see a further decline in price per unit, stabilizing around $300-$350 due to decreased market share.
- Generic versions could stabilize around $100-$150, with potential for slight reductions owing to market saturation and increased competition.
Regulatory and Market Access Factors
The U.S. FDA approved tadalafil for daily use and other indications, broadening market potential. Reimbursement policies vary by region but generally favor generics, driving down consumer prices. Entry of biosimilars and combination therapies could influence market pricing structures further.
Future Market and Price Developments
- Market Expansion: The rise of combination therapies (e.g., tadalafil with antihypertensives) could open new revenue streams.
- Price Trends: Continued generic market penetration suggests sustained downward pressure on prices.
- Innovations: New delivery mechanisms, such as long-acting formulations or novel combinations, could impact both market size and pricing models.
Key Takeaways
- The global tadalafil market is valued at ~$2.4 billion with a 6% CAGR through 2028.
- Patent expirations have led to increased generic competition, reducing prices.
- U.S. retail prices for brand Cialis hover around $500, with generics around $150.
- Market growth remains supported by aging populations, expanding indications, and regional demand shifts.
- Future pricing will depend heavily on regulatory decisions, biosimilar entry, and innovative formulations.
5 FAQs
-
What is the main driver of tadalafil's market growth?
Growing prevalence of ED, aging populations, new indications, and expanding geographic markets.
-
How will generic competition influence market prices?
Generics will likely continue to lower prices, especially in regions where patent protections have expired.
-
Are there upcoming formulations that could alter pricing?
Yes, long-acting and combination therapies may impact market dynamics.
-
What regional factors affect pricing?
Insurance coverage, reimbursement policies, and healthcare infrastructure influence retail prices across regions.
-
How does off-label use impact the market?
Off-label applications expand demand but are less predictable for pricing due to regulatory and insurance constraints.
Sources:
[1] MarketWatch, "Global Erectile Dysfunction Market," 2022.
[2] IQVIA, "Pharmaceutical Market Data," 2023.
[3] U.S. FDA, "Drug Approvals and Labeling," 2023.
[4] Brightfield Group, "Urological and Sexual Dysfunction Drugs," 2022.
[5] EvaluatePharma, "Forecasts and Price Trends," 2023.
